α-Synuclein and dopamine at the crossroads of Parkinson's disease.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Trends in Neurosciences

• Publication date

  2010-12-01

• Fields of study

  Biology, Medicine, Psychology

• Identifiers
  DOI 10.1016/j.tins.2010.09.004PMID 20961626PMCID PMC3631137
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Parkinson's disease].

  2022cited by this paper
• Genome‐Wide Association Study Confirms SNPs in SNCA and the MAPT Region as Common Risk Factors for Parkinson Disease

  2010influential reference
• Post-transcriptional Regulation of α-Synuclein Expression by mir-7 and mir-153

  2010cited by this paper
• Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis.

  2010cited by this paper
• Striatal Muscarinic Receptors Promote Activity Dependence of Dopamine Transmission via Distinct Receptor Subtypes on Cholinergic Interneurons in Ventral versus Dorsal Striatum

  2010cited by this paper
• Increased Expression of a-Synuclein Reduces Neurotransmitter Release by Inhibiting Synaptic Vesicle Reclustering after Endocytosis

  2010influential reference
• Absence of alpha-synuclein affects dopamine metabolism and synaptic markers in the striatum of aging mice.

  2010influential reference
• In Vivo RNAi-Mediated α-Synuclein Silencing Induces Nigrostriatal Degeneration.

  2010cited by this paper
• POST-TRANSCRIPTIONAL REGULATION OF ALPHA-SYNUCLEIN EXPRESSION BY MIR-7 AND MIR-153

  2010cited by this paper
• Genome-wide association studies: the key to unlocking neurodegeneration?

  2010cited by this paper
• Oxidants induce alternative splicing of alpha-synuclein: Implications for Parkinson's disease.

  2010cited by this paper
• Repression of α-synuclein expression and toxicity by microRNA-7

  2009cited by this paper
• Single Nigrostriatal Dopaminergic Neurons Form Widely Spread and Highly Dense Axonal Arborizations in the Neostriatum

  2009cited by this paper
• Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons.

  2009cited by this paper
• Genome-Wide Association Study reveals genetic risk underlying Parkinson’s disease

  2009influential reference
• Neuropathology of non-motor features of Parkinson disease.

  2009cited by this paper
• Non-motor extranigral signs and symptoms in Parkinson's disease.

  2009cited by this paper
• Molecular pathogenesis of Parkinson disease: insights from genetic studies

  2009cited by this paper
• Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human α-synuclein in transgenic mouse brain

  2009cited by this paper
• Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice.

  2008cited by this paper
• The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis.

  2008cited by this paper
• The Parkinson's disease protein α-synuclein disrupts cellular Rab homeostasis

  2008cited by this paper
• Alpha-synuclein aggregation alters tyrosine hydroxylase phosphorylation and immunoreactivity: lessons from viral transduction of knockout mice.

  2008cited by this paper
• Genetic variability in the SNCA gene influences α‐synuclein levels in the blood and brain

  2008cited by this paper
• The effect of α‐synuclein knockdown on MPP+ toxicity in models of human neurons

  2008cited by this paper
• Oxidative Stress in Parkinson's Disease

  2008cited by this paper
• α6-Containing Nicotinic Acetylcholine Receptors Dominate the Nicotine Control of Dopamine Neurotransmission in Nucleus Accumbens

  2008cited by this paper
• Silencing α-Synuclein Gene Expression Enhances Tyrosine Hydroxylase Activity in MN9D Cells

  2008cited by this paper
• Modulation of α-synuclein expression in transgenic animals for modelling synucleinopathies — is the juice worth the squeeze?

  2008cited by this paper
• Increased striatal dopamine release and hyperdopaminergic‐like behaviour in mice lacking both alpha‐synuclein and gamma‐synuclein

  2008influential reference
• Calcium, ageing, and neuronal vulnerability in Parkinson's disease.

  2007cited by this paper
• Space, time and dopamine.

  2007cited by this paper
• ‘Rejuvenation’ protects neurons in mouse models of Parkinson’s disease

  2007cited by this paper
• The ups and downs of α‐synuclein mRNA expression

  2007cited by this paper
• Neuropathology, biochemistry, and biophysics of α‐synuclein aggregation

  2007cited by this paper
• The ups and downs of alpha-synuclein mRNA expression.

  2007cited by this paper
• RNA interference‐mediated knockdown of α‐synuclein protects human dopaminergic neuroblastoma cells from MPP+ toxicity and reduces dopamine transport

  2007cited by this paper
• Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease.

  2007influential reference
• Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation.

  2007cited by this paper
• Effect of α-synuclein on the promoter activity of tyrosine hydroxylase gene

  2007cited by this paper
• Effect of alpha-synuclein on the promoter activity of tyrosine hydroxylase gene.

  2007cited by this paper
• Alpha‐synuclein inhibits aromatic amino acid decarboxylase activity in dopaminergic cells

  2006cited by this paper
• Phosphorylation of Ser-129 Is the Dominant Pathological Modification of α-Synuclein in Familial and Sporadic Lewy Body Disease*

  2006cited by this paper
• Levels of alpha‐synuclein mRNA in sporadic Parkinson disease patients

  2006cited by this paper
• Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons

  2006cited by this paper
• Faculty Opinions recommendation of Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models.

  2006cited by this paper
• High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease

  2006cited by this paper
• α-Synuclein Overexpression in PC12 and Chromaffin Cells Impairs Catecholamine Release by Interfering with a Late Step in Exocytosis

  2006influential reference
• α-Synuclein Blocks ER-Golgi Traffic and Rab1 Rescues Neuron Loss in Parkinson's Models

  2006cited by this paper
• Developmental exposure to the pesticide dieldrin alters the dopamine system and increases neurotoxicity in an animal model of Parkinson's disease

  2006cited by this paper
• Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease.

  2006cited by this paper
• α-Synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers

  2006cited by this paper
• α-Synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells

  2005cited by this paper
• K-ATP channels promote the differential degeneration of dopaminergic midbrain neurons

  2005cited by this paper
• Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease.

  2005cited by this paper
• Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection.

  2005cited by this paper
• α-Synuclein Cooperates with CSPα in Preventing Neurodegeneration

  2005cited by this paper
• Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human alpha-synuclein.

  2005cited by this paper
• A marked rise in 5-S-cysteinyl-dopamine levels in guinea-pig striatum following reserpine treatment

  2005cited by this paper
• Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration.

  2005cited by this paper
• Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha/gamma-synuclein null mutant mice.

  2004cited by this paper
• Role of alpha-synuclein in presynaptic dopamine recruitment.

  2004influential reference
• The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia

  2004cited by this paper
• Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications.

  2004cited by this paper
• Comparison of kindreds with parkinsonism and α‐synuclein genomic multiplications

  2004cited by this paper
• Alteration in α‐synuclein mRNA expression in Parkinson's disease

  2004cited by this paper
• Parkinson's disease

  2004cited by this paper
• alpha-Synuclein promoter confers susceptibility to Parkinson's disease.

  2004cited by this paper
• Role of α-Synuclein in Presynaptic Dopamine Recruitment

  2004influential reference
• Causal relation between α-synuclein locus duplication as a cause of familial Parkinson's disease

  2004cited by this paper
• Inhibition of tyrosine hydroxylase expression in alpha-synuclein-transfected dopaminergic neuronal cells.

  2004cited by this paper
• α-synuclein locus duplication as a cause of familial Parkinson's disease

  2004cited by this paper
• Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of γ‐synuclein, α‐synuclein and double α/γ‐synuclein null mutant mice

  2004cited by this paper
• Alpha-synuclein locus duplication as a cause of familial Parkinson's disease.

  2004cited by this paper
• α‐Synuclein promoter confers susceptibility to Parkinson's disease

  2004cited by this paper
• α-Synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication

  2004cited by this paper
• Alteration in alpha-synuclein mRNA expression in Parkinson's disease.

  2004cited by this paper
• Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease.

  2004cited by this paper
• Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease.

  2003cited by this paper
• Co‐ordinate transcriptional regulation of dopamine synthesis genes by α‐synuclein in human neuroblastoma cell lines

  2003cited by this paper
• The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease.

  2003cited by this paper
• Variable Dopamine Release Probability and Short-Term Plasticity between Functional Domains of the Primate Striatum

  2003cited by this paper
• Role of alpha-synuclein carboxy-terminus on fibril formation in vitro.

  2003cited by this paper
• Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease.

  2003cited by this paper
• Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders.

  2003cited by this paper
• Attenuation of dopamine transporter activity by alpha-synuclein.

  2003cited by this paper
• Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice.

  2003cited by this paper
• Oxidative stress in Parkinson's disease

  2003cited by this paper
• alpha-Synuclein locus triplication causes Parkinson's disease.

  2003cited by this paper
• Role of α-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice

  2003cited by this paper
• Part II: α-synuclein and its molecular pathophysiological role in neurodegenerative disease

  2003cited by this paper
• Attenuation of dopamine transporter activity by α-synuclein

  2003cited by this paper
• The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins?

  2003influential reference
• Role of α-Synuclein Carboxy-Terminus on Fibril Formation in Vitro†

  2003cited by this paper
• α-Synuclein Locus Triplication Causes Parkinson's Disease

  2003cited by this paper
• A role for alpha-synuclein in the regulation of dopamine biosynthesis.

  2002cited by this paper
• Parkinson-Like Neurodegeneration Induced by Targeted Overexpression of α-Synuclein in the Nigrostriatal System

  2002cited by this paper
• Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP

  2002cited by this paper
• Golgi Fragmentation Occurs in the Cells with Prefibrillar α-Synuclein Aggregates and Precedes the Formation of Fibrillar Inclusion*

  2002cited by this paper
• A Role for α-Synuclein in the Regulation of Dopamine Biosynthesis

  2002cited by this paper

• Damage-Derived Reactive Glia from a Parkinson’s Disease Model Are Neurotoxic to Substantia Nigra Dopaminergic Neurons in Naïve Animals

  2026cites this paper
• Landscape of Protein Post-Translational Modifications in Age-Related Neurodegenerative Disorders: Implications in Protein Aggregation, Altered Cellular Processes, and Therapeutics.

  2026cites this paper
• A Comprehensive Review of the Antioxidant, Antimicrobial, and Therapeutic Efficacies of Black Cumin (Nigella sativa L.) Seed Oil and Its Thymoquinone

  2025cites this paper
• Enteric nervous system dysfunction as a driver of central nervous system disorders: The Forgotten brain in neurological disease.

  2025cites this paper
• Optogenetic regulation of chloride ions in reactive astrocytes may mitigate Parkinson’s disease pathology

  2025cites this paper
• Neural and vascular contributions to sensory impairments in a human alpha-synuclein transgenic mouse model of Parkinson’s disease

  2025cites this paper
• Dopaminergic signalling in gastrointestinal health and disease

  2025cites this paper
• Synuclein and Mitochondrial Dysfunction: Regulating the Protein Import Complex toward PD Treatment?

  2025cites this paper
• Soil to Synapse: Molecular Insights into the Neurotoxicity of Common Gardening Chemicals in Alzheimer’s and Parkinson’s Disease

  2025cites this paper
• Advances in Molecular Docking Techniques for Targeting Protein Misfolding in Neurodegenerative Diseases.

  2025cites this paper
• Experimental and computational insights into the therapeutic mechanisms of resveratrol in a Drosophila α-synuclein model of Parkinson’s disease

  2025cites this paper
• Pathophysiological mechanisms of cardiovascular disorders in Parkinson’s disease

  2025cites this paper
• Optogenetic-induced α-synuclein accumulation reveals early synaptic dysfunction in experimental models of Parkinson’s disease

  2025cites this paper
• Substantia nigra and blood gene signatures and biomarkers for Parkinson’s disease from integrated multicenter microarray-based transcriptomic analyses

  2025cites this paper
• Neuroprotective potential of Zingiber officinale methanol extract in copper sulfate-induced nigrostriatal neurodegeneration in mice

  2025cites this paper
• Deciphering motor dysfunction and microglial activation in mThy1-α-synuclein mice: a comprehensive study of behavioral, gene expression, and methylation changes

  2025cites this paper
• Clinical Insights on Caloric Restriction Mimetics for Mitigating Brain Aging and Related Neurodegeneration

  2024cites this paper
• Substantia nigra alterations in mice modeling Parkinson’s disease

  2024cites this paper
• Disruption of Electroencephalogram Coherence between Cortex/Striatum and Midbrain Dopaminergic Regions in the Knock-Out Mice with Combined Loss of Alpha, Beta, and Gamma Synucleins

  2024cites this paper
• Therapeutic Implications and Regulations of Protein Post-translational Modifications in Parkinsons Disease

  2024cites this paper
• An updated review on animal models to study attention-deficit hyperactivity disorder

  2024cites this paper
• AVE0991 ameliorates dopaminergic neuronal damage in Parkinson’s disease through HOTAIRM1/miR-223-3p/α-synuclein axis

  2024cites this paper
• Reduction of alpha synuclein oligomers in preclinical models of Parkinson's disease by electrical stimulation in vitro and deep brain stimulation in vivo.

  2024cites this paper
• Molecular insights into the potential effects of selective estrogen receptor β agonists in Alzheimer's and Parkinson's diseases

  2024cites this paper
• AAV-aMTD-Parkin, a Therapeutic Gene Delivery Cargo, Enhances Motor and Cognitive Functions in Parkinson's and Alzheimer's Diseases.

  2024cites this paper
• Dopamine across timescales and cell types: Relevance for phenotypes in Parkinson's disease progression.

  2024cites this paper
• Exploring the correlation between serum α-synuclein and abnormal electroencephalography patterns in children with epilepsy, as well as electroencephalographic discharge index

  2024cites this paper
• The identification of c-Abl inhibitors as potential agents for Parkinson’s disease: a preliminary in silico approach

  2024influential citation
• Post-translational modification and mitochondrial function in Parkinson’s disease

  2024cites this paper
• Understanding Role of Pesticides in Development of Parkinson's Disease: Insights from Drosophila and Rodent Models.

  2024cites this paper
• Pharmacological Regulation of Endoplasmic Reticulum Structure and Calcium Dynamics: Importance for Neurodegenerative Diseases

  2023cites this paper
• The Synucleins and the Astrocyte

  2023cites this paper
• Phase separation and pathologic transitions of RNP condensates in neurons: implications for amyotrophic lateral sclerosis, frontotemporal dementia and other neurodegenerative disorders

  2023cites this paper
• Antioxidant Thymoquinone and Its Potential in the Treatment of Neurological Diseases

  2023cites this paper
• Potential direct role of synuclein in dopamine transport and its implications for Parkinson's disease pathogenesis.

  2023cites this paper
• Dopamine functionalized, red carbon quantum dots for in vivo bioimaging, cancer therapeutics, and neuronal differentiation

  2023cites this paper
• Young human alpha synuclein transgenic (BAC-SNCA) mice display sex- and gene-dose-dependent phenotypic disturbances.

  2023cites this paper
• In situ single-molecule investigations of the impacts of biochemical perturbations on conformational intermediates of monomeric α-synuclein

  2023cites this paper
• Correlation of Parkinson’s disease with diabetes mellitus, obesity, dyslipidemia and their association with severity of disease

  2023cites this paper
• Reduced coupling of global brain function and cerebrospinal fluid dynamics in Parkinson’s disease

  2023cites this paper
• Developmental exposure to the Parkinson’s disease-associated organochlorine pesticide dieldrin alters dopamine neurotransmission in α-synuclein pre-formed fibril (PFF)-injected mice

  2023cites this paper
• Dopamine Transmission Imbalance in Neuroinflammation: Perspectives on Long-Term COVID-19

  2023cites this paper
• Early Effects of Alpha-Synuclein Depletion by Pan-Neuronal Inactivation of Encoding Gene on Electroencephalogram Coherence between Different Brain Regions in Mice

  2023cites this paper
• Evolutionary and genomic perspectives of brain aging and neurodegenerative diseases.

  2023cites this paper
• for neuroimaging of

  2023cites this paper
• Editorial of the Special Issue: Recent Advances in Understanding of the Role of Synuclein Family Members in Health and Disease

  2023cites this paper
• Depletion of dopamine in Parkinson's disease and relevant therapeutic options: A review of the literature

  2023cites this paper
• Meclofenoxate Inhibits Aggregation of Alpha-Synuclein in vitro.

  2023cites this paper
• The identification of cianidanol as a selective estrogen receptor beta agonist and evaluation of its neuroprotective effects on Parkinson's disease models.

  2023cites this paper
• Antiparkinsonian Agents in Investigational Polymeric Micro- and Nano-Systems

  2022cites this paper
• Heterozygote Dopamine Transporter Knockout Rats Display Enhanced Cocaine Locomotion in Adolescent Females

  2022cites this paper
• Morpho‐Functional Changes of Nigral Dopamine Neurons in an α‐Synuclein Model of Parkinson's Disease

  2022cites this paper
• Pathogenesis of α-Synuclein in Parkinson’s Disease: From a Neuron-Glia Crosstalk Perspective

  2022cites this paper
• Phytoconstituents of Datura metel extract improved motor coordination in haloperidol-induced cataleptic mice: Dual-target molecular docking and behavioural studies.

  2022cites this paper
• Loss of the Synuclein Family Members Differentially Affects Baseline- and Apomorphine-Associated EEG Determinants in Single-, Double- and Triple-Knockout Mice

  2022cites this paper
• Neonatal 6-hydroxydopamine lesioning of rats and dopaminergic neurotoxicity: proposed animal model of Parkinson’s disease

  2022cites this paper
• Translocation of Distinct Alpha Synuclein Species from the Nucleus to Neuronal Processes during Neuronal Differentiation

  2022cites this paper
• Multiple checkpoints of protein clearance machinery are modulated by a common microRNA, miR-4813-3p, through its putative target genes: Studies employing transgenic C. elegans model.

  2022cites this paper
• An Overview of the Neuropharmacological Potential of Thymoquinone and its Targeted Delivery Prospects for CNS Disorder.

  2022cites this paper
• Removal of proteinase K resistant αSyn species does not correlate with cell survival in a virus vector-based Parkinson's disease mouse model.

  2022cites this paper
• Alpha-synucleinopathy reduces NMNAT3 protein levels and neurite formation that can be rescued by targeting the NAD+ pathway

  2022cites this paper
• Effects of oligomer toxicity, fibril toxicity and fibril spreading in synucleinopathies

  2022cites this paper
• Sensitive electrochemical recognition of α‐synuclein protein in human plasma samples using bioconjugated gold nanoparticles: An innovative immuno‐platform to assist in the early stage identification of Parkinson's disease by biosensor technology

  2022cites this paper
• Sensitive immunosensing of α-synuclein protein in human plasma samples using gold nanoparticles conjugated with graphene: an innovative immuno-platform towards early stage identification of Parkinson's disease using point of care (POC) analysis

  2022cites this paper
• Microfabrication atomic layer deposited Pt NPs/TiN thin film on silicon as a nanostructure signal Transducer: Electrochemical characterization toward neurotransmitter sensing

  2022cites this paper
• Reelin protects against pathological α-synuclein accumulation and dopaminergic neurodegeneration after environmental enrichment in Parkinson's disease.

  2022cites this paper
• Caenorhabditis elegans as a Model to Study Manganese-Induced Neurotoxicity

  2022cites this paper
• The Impact of SNCA Variations and Its Product Alpha-Synuclein on Non-Motor Features of Parkinson’s Disease

  2021cites this paper
• Neurodegenerative disorders and the current state, pathophysiology and management of Parkinson's disease.

  2021cites this paper
• Decoupling of global brain activity and cerebrospinal fluid flow in Parkinson’s cognitive decline

  2021cites this paper
• Influence of energy deficiency on the subcellular processes of Substantia Nigra Pars Compacta cell for understanding Parkinsonian neurodegeneration

  2021cites this paper
• Studying the effect of alpha-synuclein and Parkinson’s disease linked mutants on inter pathway connectivities

  2021cites this paper
• Comparative Analysis of MPTP Neurotoxicity in Mice with a Constitutive Knockout of the α-Synuclein Gene

  2021cites this paper
• An Overview of Alpha Synuclein Protein and Its Role in Parkinson’s disease

  2021cites this paper
• Decoupling of Global Brain Activity and Cerebrospinal Fluid Flow in Parkinson's Disease Cognitive Decline

  2021cites this paper
• Hybrid resolution molecular dynamics simulations of amyloid proteins interacting with membranes.

  2021cites this paper
• Parkinson's disease: Alterations in iron and redox biology as a key to unlock therapeutic strategies

  2021influential citation
• Alpha-Synuclein Post-translational Modifications: Implications for Pathogenesis of Lewy Body Disorders

  2021cites this paper
• Morphological Heterogeneity of the Endoplasmic Reticulum within Neurons and Its Implications in Neurodegeneration

  2021cites this paper
• Orientation of α-Synuclein at Negatively Charged Lipid Vesicles: Linear Dichroism Reveals Time-Dependent Changes in Helix Binding Mode

  2021cites this paper
• Glycoconjugate journal special issue on: the glycobiology of Parkinson’s disease

  2021influential citation
• P.0860 The absence of synuclein proteins causes behavioural impairment in a novel triple knockout mouse model

  2021cites this paper
• Microbial Infections Are a Risk Factor for Neurodegenerative Diseases

  2021cites this paper
• β-synuclein potentiates synaptic vesicle dopamine uptake and rescues dopaminergic neurons from MPTP-induced death in the absence of other synucleins

  2021cites this paper
• Recent Advances in In Vivo Neurochemical Monitoring

  2021cites this paper
• DNAJB6 suppresses alpha-synuclein induced pathology in an animal model of Parkinson's disease.

  2020cites this paper
• Saffron and Neurological Disorders

  2020cites this paper
• Decreased plasma α-synuclein in idiopathic Parkinson’s disease patients after adjusting hemolysis factor

  2020cites this paper
• Demonstration of brain region-specific neuronal vulnerability in human iPSC-based model of familial Parkinson’s disease

  2020cites this paper
• Transcriptomic signatures of brain regional vulnerability to Parkinson’s disease

  2020cites this paper
• Influence of Energy Deficiency on the Molecular Processes of Substantia Nigra Pars Compacta Cell for Understanding Parkinsonian Neurodegeneration: A Comprehensive Biophysical Computational Model

  2020cites this paper
• Role of Genes and Treatments for Parkinson’s Disease

  2020cites this paper
• Quantitative Profiling of the Human Substantia Nigra Proteome from Laser-capture Microdissected FFPE Tissue

  2020cites this paper
• Huzursuz bacak sendromu olan multipl sklerozlu hastalarda alfa-sinüklein düzeyleri

  2020cites this paper
• The Aβ aggregation modulator MRZ-99030 prevents and even reverses synaptotoxic effects of Aβ1-42 on LTP even following serial dilution to a 500:1 stoichiometric excess of Aβ1-42, suggesting a beneficial prion-like seeding mechanism.

  2020cites this paper
• Triple-Knockout, Synuclein-Free Mice Display Compromised Lipid Pattern

  2020cites this paper
• Thymoquinone as a Potential Neuroprotector in Acute and Chronic Forms of Cerebral Pathology

  2020cites this paper
• The Role of Alpha-Synuclein and Other Parkinson’s Genes in Neurodevelopmental and Neurodegenerative Disorders

  2020cites this paper
• Synuclein Deficiency Results in Age-Related Respiratory and Cardiovascular Dysfunctions in Mice

  2020cites this paper
• Interaction of Aβ42 with Membranes Triggers the Self-Assembly into Oligomers

  2020cites this paper